ImmunoGenesis doses 1st patient in phase 1/2 trial of IMGS-101 in combo with balstilimab & zalifrelimab to treat immune-excluded tumours: Houston Saturday, March 8, 2025, 18:00 Hr ...
Across the solid-tumor spectrum, many patients are burdened with metastatic, immune-excluded or immune-desert tumors that do not respond to checkpoint monoclonal antibodies. Systemically ...
来自MSN1 个月
MAGE-A4 protein promotes tumor progression by suppressing immune responses, mouse study findsIn addition, immune T cells, typically in charge of fighting the tumor, were excluded from the tumor microenvironment, reducing the ability of the immune system to eliminate the tumor. Importantly ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果